GlassScriptPhysician profile
Pankaj Talwar
NPI 1174546410
$2,716.09
in general payments reported to CMS, 2019-2025
31 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $187 · 2021: $762 · 2022: $286 · 2023: $358 · 2024: $445 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.34 | 2019-2024 | Airsupra, Breztri |
| Novo Nordisk INC | $344.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $312.79 | 2021-2024 | Ubrelvy |
| Esperion Therapeutics, INC. | $221.21 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $210.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $155.68 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $114.45 | 2019-2023 | |
| Abbott Laboratories | $113.79 | 2021-2022 | |
| Medtronic, INC. | $109.45 | 2021 | |
| Exact Sciences Corporation | $96.26 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $72.67 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $66.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.91 | 2019 | |
| Tactile Systems Technology INC | $57.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.98 | 2021-2023 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.36 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $45.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $42.78 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $28.25 | 2024 | |
| Phadia US INC. | $26.07 | 2019-2023 | Immunocap |
| Inspire Medical Systems, INC. | $25.75 | 2024 | Inspire |
| Ultragenyx Pharmaceutical INC. | $22.23 | 2021 | |
| Amarin Pharma, INC. | $21.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.75 | 2019 | |
| Genentech USA, INC. | $16.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2025 | Xifaxan |
| Dexcom, INC. | $16.30 | 2021 | |
| Daiichi Sankyo INC. | $13.87 | 2021 | |
| Horizon Therapeutics Plc | $13.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.